Issue 01
REGULATION AND LEGISLATION
─
Oregon psilocybin decriminalisation campaign says it will qualify for the November ballot.
─
DC activists submit signatures to put decriminalisation campaign on the November ballot.
─
New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.
─
Veteran’s commission pushes for increased research into cannabis and psychedelics.
BUSINESS AND INVESTMENT
─
British psychedelics firm Beckley Psytech raises US$3.7 million in Series A funding.
─
Professor David Nutt joins AWAKN Life Sciences.
─
Empower Clinics begins search for Dosed Wellness clinic site in Vancouver.
─
Former Pfizer, Yale drug discovery expert joins Mydecine Innovations’ advisory board.
─
New psychedelics firms, Psilera Bioscience and CannaGlobal Wellness, enter the market.
─
Numinus Wellness announces the launch of a clinical advisory council.
─
ATAI is utilising digital tools to improve psychedelic therapies and monitor patients.
─
Mota Ventures appoints Roger C. Clinton to advisory board of new acquisition, Verrian.
─
Field Trip’s first facility reopens and establishes ‘Basecamp’ mental wellness program for veterans.
RESEARCH AND SCIENCE
─
Kruzo Inc. and Rangsit University agree to establish a Psychedelic Research Institute.
─
Mindbloom to begin offering remote-enabled psychedelic therapy sessions in California.
─
Revive Therapeutics submits FDA application to begin Phase 3 trials for COVID-19 drug.
─
BC-based Havn Life Sciences launches to develop psilocybin products for research.
─
Columbus Community Hospital reduces opioids needed in surgery by using ketamine.
THE PSYCHEDELICS AS MEDICINE REPORT
|
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
|
| PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase. |
FEATURED ARTICLE
PSYCH Symposium at Prohibition Partners LIVE brought together world-class speakers, industry giants and pioneering investors, to discuss psychedelics and their potential to disrupt how we treat mental health. Read the highlights.
